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Lennox–Gastaut syndrome (LGS) is a severe epileptic and developmental encephalo­
pathy that is associated with a high rate of morbidity and mortality. It is characterized 
by multiple seizure types, abnormal electroencephalographic features, and intellectual 
disability. Although intellectual disability and associated behavioral problems are char­
acteristic of LGS, they are not necessarily present at its outset and are therefore not 
part of its diagnostic criteria. LGS is typically treated with a variety of pharmacological 
and non­pharmacological therapies, often in combination. Management and treatment 
decisions can be challenging, due to the multiple seizure types and comorbidities 
associated with the condition. A panel of five epileptologists met to discuss consensus 
recommendations for LGS management, based on the latest available evidence from 
literature review and clinical experience. Treatment algorithms were formulated. Current 
evidence favors the continued use of sodium valproate (VPA) as the first­line treatment 
for patients with newly diagnosed de novo LGS. If VPA is ineffective alone, evidence 
supports lamotrigine, or subsequently rufinamide, as adjunctive therapy. If seizure con­
trol remains inadequate, the choice of next adjunctive antiepileptic drug (AED) should be 
discussed with the patient/parent/caregiver/clinical team, as current evidence is limited. 
Non­pharmacological therapies, including resective surgery, the ketogenic diet, vagus 
nerve stimulation, and callosotomy, should be considered for use alongside AED therapy 
from the outset of treatment. For patients with LGS that has evolved from another type 
of epilepsy who are already being treated with an AED other than VPA, VPA therapy 
should be considered if not trialed previously. Thereafter, the approach for a de novo 
patient should be followed. Where possible, no more than two AEDs should be used 
concomitantly. Patients with established LGS should undergo review by a neurologist 
Abbreviations: AE, adverse event; AED, antiepileptic drug; CLB, clobazam; EEG, electroencephalogram; EMA, European 
Medicines Agency; FLB, felbamate; KD, ketogenic diet; LEV, levetiracetam; LGS, Lennox–Gastaut syndrome; LTG, lamotrigine; 
MAE, myoclonic-astatic epilepsy; MRI, magnetic resonance imaging; NCSE, non-convulsive status epilepticus; PER, peram-
panel; RCT, randomized controlled trial; RUF, rufinamide; QoL, quality of life; SSW, slow spike-wave; STP, stiripentol; TPM, 
topiramate; VNS, vagus nerve stimulation; VPA, sodium valproate; ZNS, zonisamide.
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specialized in epilepsy on at least an annual basis, including a thorough reassessment of 
their diagnosis and treatment plan. Clinicians should always be vigilant to the possibility 
of treatable etiologies and alert to the possibility that a patient’s diagnosis may change, 
since the seizure types and electroencephalographic features that characterize LGS 
evolve over time. To date, available treatments are unlikely to lead to seizure remission 
in the majority of patients and therefore the primary focus of treatment should always be 
optimization of learning, behavioral management, and overall quality of life.
Keywords: algorithm, antiepileptic drug, consensus, epilepsy, epileptic and developmental encephalopathy, 
Lennox–Gastaut syndrome
OveRview OF LeNNOX–GASTAUT 
SYNDROMe (LGS)
Lennox–Gastaut syndrome is a severe epileptic and develop-
mental encephalopathy, with onset typically between the ages of 
3 and 7 years (most commonly 3–5 years) (1, 2). The syndrome 
persists through adolescence and on into adulthood, and may 
also, rarely, have late onset (3). LGS often occurs de novo, but may 
also evolve from other severe infantile seizure disorders, such 
as West syndrome (infantile spasms) (4). There is no biological 
marker; it has a heterogeneous etiology. Many cases occur as 
a result of a brain abnormality caused by, for example, a brain 
insult, developmental malformation, infection, or tumor (5), or 
a genetic mutation. However, 25–33% of cases are of unknown 
cause (6, 7). LGS is therefore an electroclinical entity that arises 
from various etiologies. Accurate diagnosis of LGS is often dif-
ficult to achieve, not only because, when taken separately, the 
characteristic seizure types and electroencephalogram (EEG) 
features are not pathognomonic, but also because they evolve 
and change over time. Consequently, LGS can be difficult to 
discern from other epilepsy syndromes, particularly early in 
the natural history. However, accurate and early diagnosis 
of the syndrome is central to its effective management, since 
appropriate treatment can potentially alter a patient’s clinical 
course and thereby improve their overall prognosis (2, 4).
Definition of LGS
Although a precise definition of LGS has remained elusive, 
due to debate concerning the limits, cause(s), and diagnosis 
of the syndrome (4), two key criteria that were included in 
the original description prevail: (i) multiple seizure types, to 
include tonic, atonic, and atypical absence seizures, with tonic 
seizures predominantly occurring at night and (ii) abnormal 
EEG, consisting primarily of an interictal pattern of diffuse, 
slow spike-wave (SSW) complexes at <3Hz, occurring during 
wakefulness (1). Additional features, required as diagnostic by 
many, include paroxysmal fast rhythms (10–20 Hz) during sleep, 
mainly during non-rapid eye movement sleep, the hallmark of 
tonic seizures (8).
Although intellectual disability and associated behavioral 
problems were originally described in all patients by Lennox 
and Gastaut (1), they are not necessarily present at its outset and, 
consequently, their presence or absence are not included in the 
diagnostic criteria.
The seizure and EEG characteristics outlined above are cen-
tral features of LGS; however, additional characteristics may be 
seen. Some or all of these may be present before or at diagnosis, 
or they may evolve and change over time. Additional seizure 
types associated with LGS include the following:
•	 Epileptic spasms: LGS develops from West syndrome in 
approximately 30% of pediatric cases (9, 10) and such patients 
may continue to have epileptic spasms during evolution to 
LGS (11).
•	 Non-convulsive status epilepticus (NCSE): occurs in 50–75% of 
patients with LGS and usually consists of sub-continuous atyp-
ical absences with varying degrees of altered consciousness, 
periodically interrupted by recurring brief tonic seizures (7).
•	 Focal seizures (with or without bilateral involvement), gener-
alized tonic–clonic seizures, unilateral clonic seizures: usually 
occur in the later stages of LGS, but may sometimes precede 
the core seizure types (4).
•	 Myoclonic seizures: occur in 11–28% of patients (6, 12–15) 
and can lead to falls, but are associated with many generalized 
epilepsies and are therefore not regarded as a defining feature 
of LGS (2).
investigations at Diagnosis
Given the aforementioned difficulties associated with accurately 
diagnosing LGS, several key investigations are recommended:
•	 Sleep EEG: the use of sleep EEG recording is considered 
mandatory for LGS diagnosis, since the occurrence of tonic 
seizures from sleep and/or the presence of paroxysmal fast 
rhythms are key diagnostic criteria, even in adult patients 
(4, 16). To obtain a sleep EEG in an adult patient, prior total or 
partial sleep deprivation may be helpful.
•	 Magnetic resonance imaging (MRI): MRI is required to assess 
the presence of structural abnormalities (e.g., brain tumor/
malformation, tuberous sclerosis complex) that might eluci-
date etiology, aid differential diagnosis, and/or guide treatment 
decisions (10).
•	 Genetic investigation: LGS is essentially an electroclinical 
diagnosis. Attempts have been made to determine a possible 
genetic etiology, but the genetic architecture of LGS is highly 
heterogeneous (17, 18). Although there is no single gene for 
LGS, genetic testing (i.e., targeted resequencing, array com-
parative genomic hybridization) can be helpful in determining 
an etiology and consequent recurrence risks; it may also help 
TAbLe 1 | Examples of gene tests that might elucidate LGS genetic etiology.
Gene Association Reference
SCN1A GEFS+/Dravet syndrome/other phenotypes (20)
SLC2A1 GLUT1­deficiency syndrome (21)
STXBP1 Infantile spasms/West syndrome,  
Lennox–Gastaut syndrome
(18)
DNM1 Infantile spasms/West syndrome,  
Lennox–Gastaut syndrome
(18)
GABRB3 Infantile spasms/West syndrome,  
Lennox–Gastaut syndrome
(18)
GEFS+, generalized epilepsy with febrile seizures plus; GLUT1, glucose transporter 
type 1; LGS, Lennox–Gastaut syndrome.
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prevent unnecessary diagnostic investigations (19). Genetic 
tests that might help inform LGS etiology and diagnosis are 
outlined in Table 1.
Collaboration between the EuroEPINOMICS and Epi4K/
EPGP consortia allowed the analysis of exome-sequencing data 
from a cohort of 356 trios with LGS or infantile spasms, and 
found a total of 429 de novo mutations (17). The cohort was suf-
ficiently large to demonstrate that this represented a statistically 
significant excess in comparison with the general population, 
supporting a prominent role for de novo mutations in epileptic 
encephalopathies. Seven genes were identified as having a role 
in these epileptic encephalopathies: DNM1, ALG13, CDKL5, 
GABRB3, SCN1A, SCN2A, and STXBP1. Overall, at least 12% of 
patients were found to have an identifiable causal de novo muta-
tion (17).
Patients with trisomy 21 may present with late-onset LGS, 
characterized by frequent reflex seizures, mostly precipitated by 
sudden unexpected sensory stimulation (22).
Problems with Diagnosis
Although EEG features are central to an accurate diagnosis of 
LGS, it is important to consider that they can take time to develop, 
particularly in the very young. The SSW EEG pattern may also 
not initially be present in patients who transition to LGS from 
another epilepsy syndrome, such as West syndrome (and even 
less in children without a history of infantile spasms). Therefore, 
for patients presenting with the seizure types associated with LGS, 
particularly tonic or atonic seizures, clinicians should be alert to 
the possibility of an LGS diagnosis and proactively monitor for 
EEG abnormalities to confirm its diagnosis. It is important to 
aim to identify the EEG patterns that characterize LGS early in 
the natural history, since they may be relatively transient: one 
study conducted in 64 LGS patients over a 42-year period found 
that the mean duration of “classic” SSW complexes was 8.2 years 
(range 1–35 years; median 5.5 years) (23).
None of the seizure types associated with LGS is patho-
gnomonic and it is therefore crucial to consider a patient’s 
seizure pattern alongside their EEG features when an LGS diag-
nosis is suspected. For example, tonic or atonic drop attacks 
are a characteristic feature of LGS, occurring in approximately 
50% of patients with SSWs, but they are not diagnostic for 
LGS, since they are also observed in other epilepsy syndromes, 
such as those with predominantly myoclonic-astatic seizures 
(4). The seizure types associated with LGS can also be difficult 
to identify. Video and sleep EEG recording may be required 
to detect tonic seizures from sleep together with surface 
electromyography recording, as stiffening may be subtle (2). 
Identification and quantification of atypical absence seizures 
can be challenging, particularly in patients whose responsive-
ness is impaired by intellectual disability, and where SSW is 
prominent in the EEG.
Other factors that can make diagnosis challenging are that 
the seizure types and EEG features of LGS are not static, but 
evolve and change over time. This is an important consideration 
not only for initial diagnosis but also later in a patient’s disease 
course, since it has implications when choosing the most appro-
priate treatment. The evolving nature of LGS underlines the 
need for regular reassessment and re-evaluation, particularly 
when patients are transitioning from pediatric to adult care 
(see Transition from Childhood to Adulthood).
importance of Differential Diagnosis
In most cases, careful consideration of both clinical and EEG 
features should allow LGS to be discernible from other epilepsy 
syndromes; however, there are certain epilepsy syndromes with 
which it may be confused (2). Although myoclonic-atonic epi-
lepsy (MAE; Doose syndrome) has specific diagnostic criteria 
(24), at diagnosis the recurrent myoclonic atonic seizures seen 
as drop attacks may lead to a presumptive diagnosis of LGS. 
This particular example illustrates where delineating a correct 
syndrome diagnosis is of considerable prognostic importance; 
approximately two-thirds of patients with MAE have a favorable 
prognosis (25), whereas in LGS this is lacking. Atypical benign 
partial epilepsy of childhood can be confused with LGS because 
it has somewhat similar EEG features, but these differ from those 
of LGS in having normal or slightly slow background activity 
and in lacking fast spike discharges (>10/s), with an absence of 
tonic seizures (2). The syndrome of Epileptic Encephalopathy 
with Continuous Spike Wave of Slow Sleep may also manifest 
with drop attacks as a predominant seizure manifestation, with 
evidence of neurodevelopmental regression at presentation, 
but on evaluation although bursts of SSW are seen with atonic 
absence seizures when awake, prolonged sleep recordings have 
failed to disclose tonic seizures (26). Some forms of focal epi-
lepsy, such as those involving the supplementary sensorimotor 
area, where tonic, atonic, and drop attacks may manifest, may 
also be misdiagnosed. Seizures arising from the supplementary 
sensorimotor area result in a set of clinical phenomena that usu-
ally include brief asymmetric tonic posturing of the extremities 
with preserved consciousness (27, 28). EEG with additional 
surface electromyography electrodes can be useful in differen-
tiating symmetric or asymmetric tonic seizures. Moreover, focal 
frontal or parietal epilepsies can be differentiated from LGS as 
the interictal EEG usually shows normal background activity, the 
ictal EEG in tonic asymmetric seizures can be normal, and fast 
spike discharges are either localized over the vertex or diffuse but 
clearly asymmetric (29).
In around 50% of West syndrome cases, the emergence LGS 
is later seen (30). The progressive evolution of features of LGS, 
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and the fact that it may precede or follow other epilepsy syn-
dromes and/or share overlapping features with them, has led to 
the hypothesis that it may be a developmental form of epilepsy 
with a continuum from other forms of epilepsy and ultimately 
LGS (31–33). This further underlines the need for continual reap-
praisal and re-evaluation of diagnoses, so that treatment can be 
tailored appropriately.
Review OF CURReNT eviDeNCe FOR 
TReATMeNTS FOR LGS
Pharmacological Treatment of LGS
The evidence base for pharmacological treatment of LGS is limi-
ted. Epidemiological follow-up data and review of adults with 
LGS suggest that, with standard treatments, there is a very low 
likelihood of remission in the long term, confirming the ongoing 
challenges faced in seizure management (16, 34). It should also 
be noted that spontaneous fluctuations in the frequency and type 
of seizures are likely to occur (35). Consequently, when consider-
ing treatment response, the duration of time over which this is 
assessed also needs to be taken into account.
A Cochrane review of antiepileptic drug (AED) treatment 
for LGS, conducted in 2013, included eight studies of seven 
drugs utilized as adjunctive therapy (36). Meta-analysis was not 
possible due to differences in study designs, inclusion/exclu-
sion criteria, and outcomes. The conclusion was that no one 
drug appears highly effective in LGS over and above another: 
lamotrigine (LTG), rufinamide (RUF), topiramate (TPM), and 
felbamate (FLB) may all be useful as adjunctive therapy and 
clobazam (CLB) may be useful for drop attacks. No benefit was 
shown for cinromide or low-/high-dose thyrotropin-releasing 
hormone (36). A recent search of the literature has not revealed 
any additional randomized controlled trials (RCTs) that would 
add to this analysis to date.
Antiepileptic Drugs Licensed or Widely Used  
for LGS in Europe and the USA
Sodium Valproate (VPA)
Valproate has never been specifically licensed for use in LGS 
(Table 2). However, most patients presenting with epilepsy char-
acterized by generalized or multiple seizure types will initially be 
prescribed VPA in view of the fact that it is broad spectrum and 
highly unlikely to lead to aggravation of seizures. Consequently, 
it is likely to have been utilized first line in children present-
ing with de novo or emerging LGS. A major consideration in 
the general use of VPA has been the associated teratogenic 
and developmental risk to an unborn child of a mother taking 
VPA (37–39). International League Against Epilepsy guidelines 
recommend that VPA should be avoided where possible in 
women of childbearing potential, but recognize that, for seizure 
(or epilepsy) types where VPA is the most effective treatment, 
the risks and benefits of VPA and other treatment alternatives 
should be discussed, and that VPA should be offered as a first-
line treatment for epilepsy syndromes where it is the most 
effective treatment (40). In line with these recommendations, 
reviewing risk–benefit, conception in many with LGS is not a 
consideration and consequently the benefit of utilization of VPA 
often outweighs any risk.
Lamotrigine
Lamotrigine is licensed in Europe1 and the USA2 for the treat-
ment of seizures associated with LGS. LTG was shown to be 
effective and well tolerated in the treatment of LGS in a Phase III 
placebo-controlled RCT conducted in 169 patients with LGS (41) 
(Table  2). In addition, in a double-blind, placebo-controlled, 
crossover study conducted in 30 pediatric and adolescent patients 
with refractory generalized epilepsy, 20 of whom had LGS, LTG 
was well tolerated and a statistically significant reduction in seizure 
frequency was observed with LTG, compared with placebo (47). 
VPA inhibits the metabolism of LTG (48). Therefore, a decreased 
LTG dose is required when used as add-on to VPA therapy (see 
text footnote 1). Conversely, if VPA is subsequently discontinued, 
the LTG dose may need to be increased. Monitoring and/or dose 
adjustment of these AEDs when used in combination is recom-
mended, particularly as many experts feel that the combination 
of LTG with VPA is one of the best for the early treatment of 
LGS (49).
Rufinamide
Rufinamide is licensed in Europe3 and the USA4 as adjunctive 
treatment for seizures associated with LGS. RUF’s effectiveness 
in LGS was demonstrated in a Phase III placebo-controlled RCT 
conducted in 138 patients with LGS (42) (Table 2). This RCT was 
followed by a long-term, open-label extension study, in which all 
patients (n = 124) received RUF for a median of 432 days (50). 
Reductions in seizure frequency were maintained throughout 
the study and tolerability observed in the initial trial was also 
maintained with long-term treatment (50). A post hoc subgroup 
analysis of data from the 31 adult patients (age 18–37  years) 
included in the initial Phase III trial demonstrated that RUF had 
favorable efficacy and was generally well tolerated when used as 
adjunctive treatment for adults (51). Responder rates were 33.3% 
for RUF versus 0% for placebo (p = 0.066) for all seizures, and 
57.1 versus 10.0% (p = 0.020) for drop attacks (51). The long-term 
safety and seizure outcome of adjunctive RUF therapy was recently 
evaluated in Japanese LGS patients in an open-label extension 
study following a 12-week multicenter, placebo-controlled RCT 
(52). For the 41 patients who completed the study, the median 
percent change in the frequency of tonic–atonic seizures rela-
tive to the frequency at the start of the double-blind study was 
−39.3% (12  weeks), −40.6% (24  weeks), −46.8% (32  weeks), 
−47.6% (40 weeks), and −36.1% (52 weeks). Reduction of total 
seizure frequency was also maintained until 52 weeks. Adverse 
1 Lamictal (lamotrigine) summary of product characteristics: http://www.ema.
europa.eu/docs/en_GB/document_library/Referrals_document/Lamictal_30/
WC500008824.pdf.
2 Lamictal (lamotrigine) prescribing information: https://www.accessdata.fda.gov/
drugsatfda_docs/label/2009/020241s037s038,020764s030s031lbl.pdf.
3 Inovelon (rufinamide) summary of product characteristics: http://www.ema.
europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/
human/000660/WC500032937.pdf.
4 Banzel (rufinamide) prescribing information: http://www.accessdata.fda.gov/
drugsatfda_docs/label/2015/021911s012lbl.pdf.
TAbLe 2 | Summary of AEDs licensed or widely used for LGS in Europe and/or the USA.
AeD Phase iii efficacy in drop attacks Phase iii efficacy in other seizures  
associated with LGS
effect on cognition behavioral Aes Other considerations
VPA •	No Phase III study in LGS •	No Phase III study in LGS •	Commona AEs: confusional 
state, disturbance in attention, 
stupor, memory impairmentj
•	Rareb AEs: cognitive disorder, 
learning disorderj











•	Should not be used as first­line 
treatment in female adolescents, 
in women of childbearing potential 
and pregnant women unless 
alternative treatments are ineffective 
or not tolerated because of high 
teratogenic potential and risk of 
developmental disorders in infants 
exposed in uteroj
LTG Phase III placebo­controlled RCT in 
LGS (16­week maintenance period) 
(41):
•	Significantly greater reduction in drop 
attacksc for LTG vs. PBO (−34 vs. 
−9%; p = 0.01)
•	Significantly higher drop attack 
responder rated for LTG vs. PBO (37 
vs. 22%; p = 0.04)
•	 Freedom from drop attacks not 
reported
Phase III placebo­controlled RCT in LGS (16­week 
maintenance period) (41):
•	Significantly greater reduction in all seizures for LTG 
vs. PBO (−32 vs. −9%; p = 0.002)
•	Significantly greater reduction in tonic–clonic seizures 
for LTG vs. PBO (−36 vs. +10%; p = 0.03)
•	Significantly higher all seizure responder rated for LTG 
vs. PBO (33 vs. 16%; p = 0.01)
•	Significantly higher tonic–atonic seizure responder 
rated for LTG vs. PBO (43 vs. 20%; p = 0.007)
•	Seizure freedom not reported
Very raree AEs: confusion, 
hallucinationsk
Commona AEs: aggression, 
irritability, agitationk
•	VPA inhibits LTG glucuronidation, 
reducing its metabolism and 
increasing its half­life nearly twofold; 
therefore, lower LTG doses required 
when used concomitantly with VPAk
•	Dose increase required following 
withdrawal of concomitant VPA 
therapy
RUF Phase III placebo­controlled RCT in 
LGS (12­week treatment period) (42):
•	Significantly greater reduction in drop 
attacksf for RUF vs. PBO (−42.5 vs. 
+1.4%; p < 0.0001)
•	Significantly higher drop attack 
responder rated for RUF vs. PBO 
(42.5 vs. 16.7%; p = 0.002)
•	 Freedom from drop attacksf occurred 
in 4.1% RUF patients vs. 3.3% PBO 
patients (p = NS)
Phase III placebo­controlled RCT in LGS (12­week 
treatment period) (42):
•	Significantly greater reduction in all seizures for RUF 
vs. PBO (−32.7 vs. −11.7%; p = 0.0015)
•	Significantly higher all seizure responder rated for RUF 
vs. PBO (31.1 vs. 10.9%; p = 0.0045)
•	Significantly greater reduction in absence and 
atypical absence seizures for RUF vs. PBO (−50.6 vs. 
−29.8%; p = 0.0222)
•	Significantly greater reduction in atonic seizures for 
RUF vs. PBO (−44.8 vs. −21.0%; p = 0.0125)
•	No patients were seizure­free during the study
•	Significantly higher percentage of RUF vs. PBO 
patients experienced an improvement in seizure 
severity on parental/guardian global evaluation scale 
(53.4 vs. 30.6%; p = 0.0041)
•	Commona AE: anxietyl •	Commona AEs: weight decrease, 
anorexia, eating disorder, decreased 
appetitel
TPM Phase III placebo­controlled RCT in 
LGS (11­week double­blind treatment 
period) (43):
•	Significantly greater reduction in drop 
attacksf for TPM vs. PBO (−14.8 vs. 
+5.1%; p = 0.041)
Phase III placebo­controlled RCT in LGS (11­week 
double­blind treatment period) (43):
•	Significantly greater reduction in major seizuresg for 
TPM vs. PBO (−25.8 vs. +5.2%; p = 0.015)
•	Commona AEs: bradyphrenia, 
expressive language disorder, 
confusional state, disorientation, 
disturbance in attention, 
memory impairment, amnesia, 
cognitive disorder, mental 
impairment, psychomotor skills 
impairedm
•	Very commoni AE: 
depressionm
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AeD Phase iii efficacy in drop attacks Phase iii efficacy in other seizures  
associated with LGS
effect on cognition behavioral Aes Other considerations
•	Higher (but not significantly) drop 
attack responder rated for TPM vs. 
PBO (28 vs. 14%; p = 0.071)
•	During double­blind phase, 2.2% 
TPM vs. 0% PBO patients were free 
from drop attacksf
•	During maintenance period (last 
8 weeks of double­blind phase), 
10.9% TPM vs. 0% PBO patients 
were free from drop attacksf
•	Significantly higher major seizureg responder rated for 
TPM vs. PBO (33 vs. 8%; p = 0.002)
•	During double­blind phase, 2.2 TPM vs. 0% PBO 
patients were free from major seizuresg
•	Significantly more TPM vs. PBO patients experienced 
improvement in seizure severity on parental global 
evaluation scale (p = 0.037)
•	Many uncommonh cognitive 
AEsm
•	Commona AEs: 
aggression, mood altered, 
agitation, mood swings, 




CLB Phase III placebo­controlled RCT in 
LGS (12­week maintenance period) 
(44):
•	Significantly greater reduction in drop 
attacks for CLB vs. PBO: average 
weekly rates decreased 12.1% for 
PBO vs. 41.2% (p = 0.0120), 49.4% 
(p = 0.0015) and 68.3% (p < 0.0001) 
for CLB 0.25, 0.5, and 1 mg/kg/day, 
respectively
•	Significantly higher drop attack 
responder rated for CLB vs. PBO: 
31.6% for PBO vs. 43.4% (p = NS), 
58.6% (p = 0.0159), and 77.6% 
(p < 0.0001) for CLB 0.25, 0.5, and 
1.0 mg/kg/day, respectively
•	Rate of freedom from drop attacks 
was 3.5% for PBO vs. 7.5, 12.1, 
and 24.5% for CLB 0.25, 0.5, and 
1 mg/kg/day, respectively (statistical 
comparison not valid due to low 
patient numbers)
Phase III placebo­controlled RCT in LGS (12­week 
maintenance period) (44):
•	Significantly greater reduction in total seizures for 
CLB vs. PBO: average weekly rates decreased 9.3% 
for PBO vs. 34.8% (p = 0.0414), 45.3% (p = 0.0044) 
and 65.3% (p < 0.0001) for CLB 0.25, 0.5, and 
1 mg/kg/day, respectively
•	AEs include: slowing of reaction 
time, confusion, slowed or 
indistinct speechn
•	Anterograde amnesia may 
occur, especially at higher 
dosesn
•	AEs include: numbed 
emotions, restlessness, 
irritability, acute 
agitational states, anxiety, 
aggressiveness, delusion, 




•	Amnesia effects may 
be associated with 
inappropriate behaviorn
•	Tolerance and physical and/or 
psychic dependence may develop, 
especially during prolonged usen: 
in a long­term, single­center LGS 
study, tolerance developed in 48% 
of initial responders (45)
•	Discontinuation may result in 
withdrawal or rebound phenomenan
•	Therapeutic benefit must be 
balanced against the risk of 
habituation and dependence during 
prolonged usen
•	May change VPA plasma levels 
when used concomitantly; plasma 
levels of VPA should therefore be 
monitoredn
•	May decrease LTG plasma levels 
(expert opinion)
FLB Placebo­controlled RCT in LGS (70­day 
treatment period; 56­day maintenance 
period) (46):
•	During treatment period, significantly 
greater reduction in atonic seizures 
for FLB vs. PBO (−34 vs. −9%; 
p = 0.01); 3/28 FLB­treated patients 
vs. 0/22 PBO­treated patients had no 
atonic seizures
Placebo­controlled RCT in LGS (70­day treatment 
period; 56­day maintenance period) (46):
•	During treatment period, significantly greater 
reduction in parental counts of all seizures for FLB 
vs. PBO (−19 vs. +4%; p = 0.002); no patients were 
seizure­free
•	During maintenance period, significantly greater 
reduction in parental counts of all seizures for FLB 
vs. PBO (−26 vs. +5%; p < 0.001); 4/37 FLB­treated 
patients vs. 1/36 PBO­treated patients had no 
seizures
In controlled pediatric LGS 
studies, 6.5% of patients reported 
abnormal thinkingo
•	 Frequent AEs: agitation, 
psychological disturbance, 
aggressive reactiono
•	 Infrequent AEs: 
hallucination, euphoria, 
suicide attempto
•	Black box warning over risk of 
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•	During maintenance period, 
significantly greater reduction in 
atonic seizures for FLB vs. PBO  
(−44 vs. −7%; p = 0.002); 5/28  
FLB­treated patients vs. 0/22  
PBO­treated patients had no  
atonic seizures
•	During treatment period, reduction in generalized 
tonic–clonic seizures was −28% for FLB vs. +11% 
for PBO (p = NS); 2/16 FLB­treated patients vs. 1/13 
PBO­treated patients had no generalized tonic–clonic 
seizures
•	During maintenance period, significantly greater 
reduction in generalized tonic–clonic seizures for 
FLB vs. PBO (−40 vs. +12%; p = 0.017); 7/16 FLB­
treated patients vs. 1/13 PBO­treated patients had 
no generalized tonic–clonic seizures
•	During maintenance period, significantly higher 
parent/guardian global evaluation scores for FLB vs. 
PBO from day 49 onward (p < 0.001)
•	 In controlled pediatric LGS 
studies, 16.1% of patients 
reported nervousness and 
6.5% of patients reported 
emotional labilityo
•	Only available for limited use in 
Europe on a patient­by­patient 
basis, due to risk of aplastic anemia 
and liver failure




cTonic, atonic, and major myoclonic seizures.
d≥50% seizure frequency reduction from baseline.
e<1/10,000.
fTonic–atonic seizures.
gDrop attacks and tonic–clonic seizures.
h≥1/1,000 to <1/100.
i≥1/10.
jEpilim (sodium valproate) Summary of Product Characteristics: https://www.medicines.org.uk/emc/medicine/6781.
kLamictal (lamotrigine) Summary of Product Characteristics: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Lamictal_30/WC500008824.pdf.
lInovelon (rufinamide) Summary of Product Characteristics: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000660/WC500032937.pdf.
mTopamax (topiramate) Summary of Product Characteristics: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Topamax_30/WC500018620.pdf.
nFrisium (clobazam) Summary of Product Characteristics: http://www.medicines.org.uk/emc/medicine/8298/SPC/Frisium+Tablets+10+mg.

















ber 2017 | Volum
e 8 | A
rticle 505
TAbLe 2 | Continued
8
Cross et al. Management of Lennox–Gastaut Syndrome
Frontiers in Neurology | www.frontiersin.org September 2017 | Volume 8 | Article 505
events (AEs) were mild or moderate, except for transient seizure 
aggravation in three patients. AEs resulting in discontinuation of 
RUF were decreased appetite, drug eruption, and worsening of 
underlying autism (52).
Topiramate
Topiramate is licensed in Europe5 and the USA6 as adjunctive 
therapy for the treatment of seizures associated with LGS. TPM 
was shown to be effective in the treatment of LGS in a Phase III 
placebo-controlled RCT conducted in 98 patients with LGS (43) 
(Table 2). Ninety-seven patients completing the RCT continued 
into an open-label extension study with flexible dosing (53). For 
patients who completed 6  months of treatment (n  =  84), the 
drop attack responder rate (response defined as ≥50% reduction 
from RCT baseline) was 55 and 15% of patients had no drop 
attacks for  ≥6  months (53). TPM was well tolerated and 71% 
of patients were retained on therapy for ≥3  years. Overall, 5% 
of patients reported behavioral problems (53). TPM has a high 
association with cognitive and behavioral AEs and may, rarely, 
cause Stevens–Johnson syndrome (see text footnote 5).
Clobazam
Clobazam is licensed in Europe7 as adjunctive therapy in 
epilepsy, and in the USA8 as adjunctive treatment for seizures 
associated with LGS. The effectiveness of CLB in the treat-
ment of LGS was demonstrated in a placebo-controlled Phase 
III RCT conducted in 238 patients with LGS (44) (Table  2). 
Patients completing this RCT and a previous Phase II study (54) 
were eligible to enter a long-term, open-label extension study 
(n  =  267) (55). Seizure frequency reduction was maintained 
over the long term: median reductions from baseline in drop 
attacks and total seizures were −92% (n  =  113) and −82% 
(n = 118), respectively, after 3 years, and −91% (n = 42) and 
−85% (n = 43), respectively, after 5 years (55). At Years 1 and 3, 
14% of patients who were initial responders (defined as ≥50% 
seizure reduction from baseline to Month 3) had lost their 
responses, potentially indicating tolerance (55).
Important considerations in the use of CLB are that it is 
associated with a range of cognitive and behavioral AEs as well 
as a reported high risk of tolerance. The therapeutic benefit of 
CLB must therefore be balanced against the risk of habituation 
and dependence during prolonged use. Studies suggest, however, 
that only approximately one-third of patients develop tolerance 
(56, 57). CLB can be useful in the treatment of “difficult 
phases”/“crisis episodes” of LGS, such as the occurrence of cluster 
seizures, prolonged absences, and NCSE. Consequently, due to 
the risk of tolerance, CLB should generally only initially be con-
sidered for use on an intermittent basis over a period of 3–5 days 
5 Topamax (topiramate) summary of product characteristics: http://www.ema.
europa.eu/docs/en_GB/document_library/Referrals_document/Topamax_30/
WC500018620.pdf.
6 Topamax (topiramate) prescribing information: http://www.accessdata.fda.gov/
drugsatfda_docs/label/2012/020844s041lbl.pdf.
7 Frisium (clobazam) summary of product characteristics: http://www.medicines.
org.uk/emc/medicine/8298/SPC/Frisium+Tablets+10+mg.
8 Onfi (clobazam) prescribing information: http://www.accessdata.fda.gov/drug-
satfda_docs/label/2011/202067s000lbl.pdf. 
(expert opinion). That aside, particularly when drop attacks 
are problematic, CLB can be considered for regular use with 
awareness of the possibility of habituation. When used acutely, 
CLB does not appear to be associated with exacerbation of tonic 
seizures or status epilepticus, unlike some other benzodiazepines 
(expert opinion).
Felbamate
In view of an early suggestion of a high risk of aplastic anemia 
and acute liver failure, FLB has not been approved for use by the 
European Medicines Agency (EMA). Nevertheless, it can be an 
extremely useful medication and is approved for limited use in 
some European countries, on a patient-by-patient basis (58). 
The effectiveness of adjunctive FLB treatment in LGS was dem-
onstrated in a placebo-controlled RCT (46) (Table  2). Patients 
completing this trial could continue into a 12-month, open-label 
extension study, during which improvement in seizure control 
observed in the initial trial was sustained: at Month 12, responder 
rates (response defined as >50% reduction from RCT baseline) 
were approximately 50% for total seizures and approximately 
67% for astatic seizures (59). In the USA, FLB carries a black box 
warning and is licensed as monotherapy or adjunctive therapy for 
treatment of seizures associated with LGS only in patients who 
respond inadequately to other treatments and whose epilepsy 
is so severe that a risk of aplastic anemia and/or liver failure is 
deemed acceptable in light of the benefits conferred by its use.9 
Due to its known risks and associated licensing restriction, FLB 
has a limited role in the management of LGS.
Use of Other Pharmacological Agents  
in the Treatment of LGS
Cannabidiol has some evidence of efficacy and an adequate 
safety profile when used as adjunctive therapy in children 
and young adults with treatment-resistant epilepsies, includ-
ing LGS and Dravet syndrome (60, 61). It is currently being 
assessed as a potential adjunctive treatment for children and 
adults with LGS in Phase III clinical trials (ClinicalTrials.gov10 
identifiers: NCT02318602, NCT02224690, NCT02224560, and 
NCT02318537). In the first of these trials to report results,11 
adjunctive cannabidiol was shown to significantly reduce the 
monthly frequency of drop attacks over a 14-week treatment 
period (primary endpoint), compared with placebo, in patients 
aged 2–55  years with a confirmed diagnosis of drug-resistant 
LGS (p = 0.0135). Cannabidiol was generally well tolerated and 
the most common AEs (>10% of cannabidiol-treated patients) 
were diarrhea, somnolence, decreased appetite, pyrexia, and 
vomiting (see text footnote 11). Some of these side effects may 
be attributable to comedication; cannabidiol is a potent inhibitor 
of enzymes in the cytochrome P450 pathway, and a definitive 
interaction has been reported with at least CLB (62).
9 Felbatol (felbamate) prescribing information: http://www.accessdata.fda.gov/
drugsatfda_docs/label/2009/020189s022lbl.pdf. 
10 ClinicalTrials.gov: https://clinicaltrials.gov/. 
11 GW Pharmaceuticals Press Release, 27 June 2016: http://ir.gwpharm.com/
releasedetail.cfm?ReleaseID=977116. 
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Despite having scarce evidence of effectiveness specifically 
in LGS, some broad-spectrum AEDs, including levetiracetam 
(LEV), zonisamide (ZNS), and perampanel (PER), may be useful. 
An open-label, multicenter, observational clinical study assessed 
the efficacy and tolerability of adjunctive LEV in 55 patients 
with LGS over an 8-week maintenance period (63). Thirty-two 
(58.2%) patients experienced >50% seizure frequency reduction 
and 15 (27.3%) became seizure free; a > 50% seizure frequency 
reduction was observed in seven of 12 (58.3%) patients with drop 
attacks. The most common AE was hyperactivity (12.7%) (63). 
A Korean multicenter study assessed the efficacy and safety of 
adjunctive ZNS in 62 patients with LGS in whom therapy was 
maintained for ≥12 months (64). Overall, 32 (51.6%) patients 
experienced >50% seizure frequency reduction, of whom three 
achieved seizure freedom. AEs included transient somnolence 
and anorexia (64). A multicenter, observational, retrospective 
survey was conducted of 58 children and adolescents with 
various refractory epilepsies, including five with LGS, who 
were treated with adjunctive PER (65). After the first 3 months 
of therapy, the responder rate (≥50% seizure frequency reduc-
tion) for all included patients was 31% (18/58) overall and five 
patients (9.1%) achieved seizure freedom. Seizure aggravation 
was observed in five (9.1%) patients and the most frequently 
reported AEs were reduced vigilance or fatigue (n  =  16) and 
behavioral changes (n = 14) (65).
Steroids may occasionally be helpful for controlling atypical 
absence seizures, drop attacks, and NCSE, but relapse is com-
mon. No RCT of steroids in LGS has yet been conducted (4). In 
addition, prolonged use of steroids is associated with serious AEs, 
including growth suppression, hyperlipidemia, and osteoporosis 
(66). It is recommended that steroids only be used for “crisis” 
periods with a clear plan for short-term use and wean, avoiding 
long-term use.
Non-Pharmacological Treatment of LGS
Ketogenic Diet (KD) Therapy
The KD is a high-fat diet, designed to mimic the metabolic effects 
of starvation, which can be administered in a variety of ways (e.g., 
classical KD, medium chain triglyceride KD, modified KD). In a 
placebo-controlled RCT conducted in 145 children with drug-
resistant epilepsies, the responder rate (>50% seizure frequency 
reduction) after 3  months was significantly higher for the KD 
versus no change in treatment (38 vs. 6%; p < 0.0001) (67). The 
most common AEs were constipation, vomiting, hunger, and lack 
of energy (67). In a further RCT, conducted only in children with 
LGS, children were fasted and subsequently had seizure counts 
and EEG (68). They were then all commenced on the KD, but 
were randomized to receive a glucose or saccharin drink, the 
former expecting to alleviate the ketosis. This was a crossover 
trial, so, at 6 days, each were again fasted and then initiated on 
the KD with the contrary drink. At the end of the study, the dif-
ference in seizure counts between the two groups did not quite 
reach significance. There were, however, methodological flaws to 
the study; the glucose group never lost their ketosis, and seizure 
counts were initiated after fasting (68). Several open-label stud-
ies have investigated the effectiveness of KD therapy specifically 
in patients with LGS. In a single-center retrospective review of 
71  patients with LGS treated with the KD, the responder rate 
(>50% seizure frequency reduction) after 6 months was 51%; 23% 
of patients experienced >90% seizure reduction and one patient 
(1%) achieved seizure freedom (intention-to-treat analysis) (69). 
Similar results were observed after 12 months (69). In a further 
retrospective study of 47 patients with LGS treated with KD 
therapy at a single center in China, responder rates (≥50% seizure 
frequency reduction) after 3 and 6  months were 49 and 53%, 
respectively, and 10% of patients were seizure free after 6 months 
(70). Early improvement in the EEG background pattern and a 
reduction in interictal epileptic discharges were associated with 
significant seizure reduction, compared with the absence of such 
EEG changes (p < 0.01) (70). In a single-center prospective study, 
20/61 patients with LGS were treated with KD therapy (71). After 
18 months, 15 (75%) patients remained on the diet, 8 (40%) were 
responders (≥50% seizure frequency reduction), and 3 (15%) 
were seizure free (71). In another single-center retrospective 
review of 25 children with LGS treated with the modified Atkins 
diet (in which carbohydrate intake was restricted to 10 g/day), 
2 (8%) patients were seizure free, and 12 (48%) were responders 
(>50% seizure frequency) after 3 months (72). After 6 months, 
11 (44%) patients remained on the diet, 3 (12%) were seizure 
free, and all 11 (44%) were responders. After 1  year, 9 (36%) 
patients remained on the diet, 3 (12%) were seizure free, and all 
9 (36%) were responders (72). A literature review of 18 studies 
that included outcome data specifically for LGS patients found 
that 88/189 (47%) children experienced >50% seizure frequency 
reduction after 3–36 months of KD therapy (69).
As with pharmacological treatment options, the effective-
ness of KD therapy is dependent on patient adherence, which 
may be affected by an individual’s food preferences, particularly 
in the presence of coexistent rigid behavior (e.g., associated 
with autism). Its use therefore requires a dedicated KD team 
and committed carers. Studies conducted in LGS patients 
generally did not report difficulties in administering the diet 
(69–72). Although reported AEs with KD therapy may be 
relatively common, most can generally be alleviated by mak-
ing adjustments to the diet, and successful implementation 
may allow AED treatment(s) to be tapered and discontinued. 
Another advantage of the KD is that, if a response is to occur, it 
is usually observed within 3 months, allowing the effectiveness 
of this treatment option in an individual patient to be assessed 
relatively quickly (expert opinion). However, consideration 
has to be given to duration of treatment in responders, and the 
risk–benefit of long-term utilization taken into consideration 
at all times (73).
Resective Surgery
Lennox–Gastaut syndrome is an electroclinical syndrome, 
which may have focal pathology as etiology. Successful surgi-
cal outcomes have been reported in patients with a congenital 
brain abnormality that was predominantly focal on MRI, despite 
most of the epileptiform discharges being generalized (74). It is 
mandatory to look for a potential localized brain abnormality 
in patients with LGS, although this is not frequently found. 
Early-onset epilepsy, associated with a localized brain lesion, 
can evolve to an electroclinical picture mimicking LGS, when 
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resective surgery may be curative. Consequently, a high index 
of suspicion should be utilized when assessing particularly 
atypical presentations with high-quality neuroimaging. When 
no lesion is identified, patients can be treated with palliative 
surgery [vagus nerve stimulation (VNS) or corpus callo-
sotomy—see Vagus Nerve Stimulation and Corpus Callosotomy 
sections]. After corpus callosotomy or VNS therapy, generalized 
epileptiform discharges may be more localized and it may there-
fore be appropriate to re-evaluate the patient for the presence 
of a seizure focus following these procedures (75). However, in 
the absence of a definitive structural lesion, resective surgery is 
unlikely to be of benefit.
Vagus Nerve Stimulation
The use of VNS in drug-resistant epilepsy is well established (76), 
with some evidence of effectiveness in LGS (76–81). A six-center, 
retrospective study evaluated the effectiveness of VNS therapy in 
50 patients with LGS, by comparing pre- and postimplantation 
seizure frequency (79). Median reductions in total seizures were 
42% at 1 month, 58.2% at 3 months, and 57.9% at 6 months post-
implantation (p < 0.0001 at each timepoint). Similarly, median 
reductions in drop attacks were 47% at 1 month (p <  0.0001), 
55% at 3 months (p < 0001), and 88% after 6 months (p = 0.0002), 
and median reductions in atypical absence seizures were 48, 73, 
and 81% after 1, 3, and 6 months, respectively (statistical signifi-
cance not stated). In five patients who had previously undergone 
corpus callosotomy, reduction in total seizures was 73% after 
3 months and 69% after 6 months (79). In a single-center retro-
spective study conducted in Korea, 10 LGS patients who under-
went VNS were followed up for 24 months (80). Seven (70.0%) 
patients were responders (>50% seizure frequency reduction) 
and two (20.0%) experienced >75% seizure frequency reduction. 
These results were similar to those observed for 14 LGS patients 
who underwent corpus callosotomy at the same center (80). 
A pan-European, retrospective, multicenter study investigated 
the effectiveness of VNS in 347 children with drug-resistant epi-
lepsy over a follow-up period of up to 24 months (81). In patients 
with LGS, responder rates at 6, 12, and 24 months after implanta-
tion were 28.5% (35/123), 32.9% (48/146), and 39.1% (34/87), 
respectively (81). These responder rates in LGS are consistent 
with responder rates for VNS in other types of epilepsy.
An evidence-based guideline published by the American 
Academy of Neurology included a pooled analysis of 113 patients 
with LGS treated with VNS in four studies, demonstrating a 
responder rate of 55% (77). On the basis of this evidence, the 
academy recommended that VNS may be considered in patients 
with LGS (Level C) (77). VNS does not interact with AEDs. AEs 
are mainly stimulation related, mild-to-moderate in severity, 
reversible, and tend to decrease over time, seldom necessitating 
removal of the device (82). Patients treated with VNS appear to 
show continuing improvement over time and some demonstrate 
improvement in alertness (83). Although VNS is less invasive 
than callosotomy, it involves the implantation of a device, to 
which some patients and/or parents/guardians may be averse. 
An advantage of VNS is that it can be used in conjunction with 
other forms of pharmacological and non-pharmacological thera-
pies, including callosotomy (79).
Corpus Callosotomy
Corpus callosotomy is particularly effective in the treatment of 
atonic seizures and drop attacks, and has been shown to be more 
effective than VNS in this setting (84). This finding has been 
supported by a meta-analysis that compared seizure outcomes 
in nine studies in which corpus callosotomy was used to treat 
LGS with 17 studies in which VNS was used (85). Atonic seizure 
responder rate (>50% reduction) was significantly higher for cor-
pus callosotomy versus VNS (80.0 vs. 54.1%; p < 0.05), as was the 
proportion of patients experiencing a >75% reduction in atonic 
seizure frequency (70.0 vs. 26.3%; p < 0.05). For all other seizure 
types and for total seizures, there were no statistically significant 
differences between VNS and corpus callosotomy (85).
In a study that compared the long-term (2 years) outcomes 
of patients with generalized epilepsy of the Lennox-Gastaut 
or Lennox-like type who underwent callosotomy (n  =  24) or 
VNS (n = 20), both procedures were shown to be effective for 
atypical absences, generalized tonic–clonic seizures, and tonic 
seizures (86). Callosotomy was particularly effective in reducing 
the frequency of atonic seizures, whereas VNS was ineffective. 
In contrast, callosotomy was ineffective in reducing myoclonic 
seizures, whereas VNS was effective (86). A retrospective study 
conducted in Taiwan investigated the role of West syndrome 
in postcallosotomy seizure outcome in patients with LGS (87). 
Seventy-four LGS patients who underwent corpus callosotomy 
were followed up for more than 4 years, of whom 21 had a history 
of West syndrome and 53 did not. Overall, 16/21 (76.2%) patients 
who had a history of West syndrome and 29/53 (54.7%) patients 
who did not have history of West syndrome were responders 
(>50% seizure frequency reduction). There was no statistically 
significant difference in outcomes between the groups, indicat-
ing that a history of West syndrome does not appear to influence 
postcallosotomy outcomes in LGS (87). A prospective study 
conducted in 60 school-aged children with LGS compared the 
long-term effects of anterior corpus callosotomy versus AED 
treatment on seizure control, intelligence quotient, and quality 
of life (QoL) (88). Seizure freedom rates in the callosotomy 
versus AED treatment groups were 17.4 versus 2.9% at 1 year, 
13.0 versus 5.9% at 2 years, and 8.7 versus 2.9% at 5 years (sta-
tistically significant at all timepoints). Significant differences 
in favor of callosotomy were also found for mean changes in 
intelligence quotient and overall QoL after 2 years, which were 
not related to postoperative outcomes of seizure control (88). 
A study conducted in 10 LGS patients demonstrated that VNS 
can be effective in controlling residual seizures following corpus 
callosotomy (89).
Based on available evidence and clinical experience, calloso-
tomy appears to be particularly effective for treating drop attacks 
and it is therefore recommended that it should be considered in 
LGS patients for whom drop attacks are especially problematic. 
Callosotomy may be considered early in the clinical course 
of such patients, or when other treatment options have been 
tried, depending primarily on patient/parent/guardian choice. 
Following callosotomy, other treatments may also be used, 
if required, including VNS. There is currently no evidence for 
a disconnection syndrome in children with LGS who undergo 
callosotomy.
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GeNeRAL PRiNCiPLeS OF LGS 
TReATMeNT
Lennox–Gastaut syndrome is a complex epileptic and develop-
mental encephalopathy, with an extremely poor prognosis for 
long-term seizure control and cognitive outcome. Even with 
current and new pharmacological agents, seizure freedom is 
highly unlikely to be achieved (34). During all stages of life, 
management of LGS must carefully balance the need for treat-
ment against side effects, with the patient’s overall QoL always 
being the primary focus (3), seeking optimal seizure control, 
rather than, necessarily, complete seizure freedom. Fluctuations 
in seizure frequency are likely to occur regardless of interven-
tion, and the effect of an intervention should be assessed over 
an appropriate period of time (35). The aims of treatment may 
differ according to patient age and stage of disease, and this 
should be a primary consideration during patient re-evaluation 
and transition of care. In many patients, the main aim of LGS 
treatment is not necessarily to achieve seizure freedom, but to 
suppress or reduce the frequency of the more disabling seizure 
types (4). It is important to consider that a patient’s QoL may 
be impaired more by the side effects of treatment than by the 
seizures themselves (4) and clinicians should always be vigilant 
for adverse drug effects.
Treatment goals should be agreed with the parents/caregivers 
and, if possible, the patient before selecting a treatment plan (4). 
Assessments of QoL are more important in the long term than 
measurements of seizure outcome (4). Standardized measures of 
cognitive performance and behavior are also important over the 
long term (4). Treatment plans should be regularly reassessed, and 
agreement of the treatment plan should include a comprehensive 
and transparent explanation of the type, severity, and duration 
of AEs that might be expected to occur, how these should be 
managed, and the reasons for fast or slow titration/tapering off 
of AEDs. As for all types of epilepsy, polytherapy (AEDs and 
comorbidity-associated medications) should be rationalized 
and minimized whenever possible. The rationale/need for 
specific AEDs should be considered routinely as part of patient 
re-evaluation. In addition, clinicians should proactively ask the 
patient/parent/caregiver about AEs and not expect spontaneous 
reporting.
TReATMeNT ALGORiTHMS FOR LGS
The following recommendations and practical advice are the 
authors’ expert opinion, based on the available evidence and their 
clinical experience.
The full clinical features diagnostic of LGS may evolve with time, 
and this must consequently remain a consideration with regard 
to planning therapy in young children presenting with multiple 
seizure types. Since it may take time for patients to develop all the 
clinical and EEG features of LGS, it is recommended that—once 
all attempts to rule out other diagnoses have been undertaken— 
a patient presenting with symptoms suggestive of LGS should 
be treated as though they have LGS (as outlined in the Section 
“Newly Diagnosed Patients with LGS”) until their full clinical/
EEG profile becomes clear.
Newly Diagnosed Patients with LGS
The treatment algorithm for a newly diagnosed patient with LGS 
is presented in Figure 1.
Patients with De Novo LGS
For a patient presenting with newly diagnosed de novo LGS, the 
recommended first-line treatment is VPA (Figure  1). If VPA 
therapy does not provide adequate seizure control, which is 
almost always the case, LTG should be added as the first adjunc-
tive therapy. Since VPA inhibits LTG metabolism, a decreased 
LTG dose with slow titration should be used. If VPA plus LTG 
does not provide adequate seizure control, RUF should be 
initiated as adjunctive therapy. Once RUF has been initiated, 
attempts should be made to discontinue either VPA or LTG, and, 
if VPA is discontinued, the LTG dose should be increased. When 
considering adding an adjunctive therapy, every attempt should 
be made to discontinue one of the two previous AEDs once the 
new AED has been introduced, since there is no evidence for the 
effectiveness of more than two AEDs in combination, and the use 
of multiple AEDs unnecessarily raises the risk of side effects and/
or drug–drug interactions.
If adequate seizure control is not achieved with the addition 
of RUF, the choice of the next adjunctive AED should be dis-
cussed with the patient/parent/caregiver/clinical team, based on 
the patient’s clinical profile and patient/parent/caregiver prefer-
ence (e.g., available formulations). When discussing further AED 
options, the following points should be considered:
•	 Topiramate is licensed for LGS but has a greater potential for 
cognitive and behavioral adverse effects than other marketed 
AEDs.
•	 Consideration may be given to short-term treatment with 
CLB, temporarily increasing the AED load. There is a risk 
of tolerance, dependence, and cognitive/behavioral AEs. 
Consequently, CLB should preferably be used on an intermit-
tent, short-term (3–5 days) basis when “crisis” episodes occur. 
Such crisis episodes include sustained absence seizures (dura-
tion >1  day), cluster seizures, and NCSE. This aside, where 
tolerance is not an issue, CLB may prove a useful adjunctive 
AED, particularly where drop attacks are troublesome.
•	 Felbamate is not licensed by the EMA due to associated risks of 
aplastic anemia and liver failure. It should only be used when 
other treatment options have failed and then only when the 
potential benefits of FLB treatment are thought to outweigh 
its risks. The use of FLB is likely to be country specific. If used, 
close monitoring (regular blood counts and liver function 
tests) is highly recommended.
Several AEDs that do not have a specific license for LGS may 
nevertheless be considered as adjunctive therapy options. LEV, 
ZNS, and PER have demonstrated some evidence of effectiveness 
in LGS. All are broad-spectrum in their modes of action and may 
therefore be useful in treating multiple seizure types. LEV par-
ticularly may be a useful adjunct as it has few interactions with 
other medications. Ethosuximide can be useful for the treatment 
of absence seizures, but should always be combined with an AED 
that is effective in treating generalized tonic–clonic seizures and 
tonic/atonic seizures, since it is not effective for these seizure 
FiGURe 1 | Treatment algorithm for a newly diagnosed patient with LGS. aNot in combination and only for intermittent, short­term treatment of “crisis” episodes.  
bIn combination with VPA and/or CLB. AE, adverse event; AED, antiepileptic drug; CBD, cannabidiol; CBZ, carbamazepine; CLB, clobazam; ESL, eslicarbazepine 
acetate; ETX, ethosuximide; FLB, felbamate; LEV, levetiracetam; LGS, Lennox–Gastaut syndrome; LTG, lamotrigine; OXC, oxcarbazepine; PB, phenobarbital;  
PER, perampanel; PHT, phenytoin; RUF, rufinamide; STP, stiripentol; TGB, tiagabine; TPM, topiramate; VPA, sodium valproate; ZNS, zonisamide.
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types. Benzodiazepines other than CLB may be considered for 
intermittent, short-term use for “crisis” episodes (as recom-
mended for CLB), but should not be used in combination with 
each other. Although there is no published evidence to support 
the efficacy of stiripentol (STP) in treating LGS, it can be used 
in combination with VPA and/or CLB. The usual approach is 
to add STP to VPA and subsequently add a small dose of CLB, 
if required. It should be noted that STP will increase VPA and 
CLB levels, so some dose adjustment will be required. There is 
also emerging evidence that cannabidiol may be effective and 
well tolerated as adjunctive therapy in LGS patients (see text 
footnote 11), although this requires confirmation in further tri-
als and long-term safety studies. Carbamazepine, oxcarbazepine, 
eslicarbazepine acetate, tiagabine, and phenytoin should only be 
used with caution, due to the potential risk of aggravation of 
drop attacks with a myoclonic component (expert opinion).
The use of non-pharmacological treatment approaches should 
be considered alongside the use of AEDs and discussed from 
the outset as part of the patient’s treatment plan. An evaluation 
regarding resective surgery must be considered in all patients, 
particularly those with LGS with structural etiology who have 
lesions predominantly in one hemisphere or tuberous sclerosis. 
Some patients/parents/caregivers may choose to try KD therapy 
relatively early on in the patient’s treatment pathway. If this is the 
case, the KD can be tried if VPA plus LTG does not provide an 
adequate seizure response, before RUF is initiated. Alternatively, 
the KD may be introduced later, when multiple AEDs have been 
tried. Since a response to the KD is usually observed within 
3 months (90), this therapeutic option can be explored relatively 
quickly. As callosotomy involves surgery, its use will largely depend 
on patient/parent/caregiver choice. Since it is effective for drop 
attacks, callosotomy may be considered as an early treatment 
option in patients for whom drop attacks are particularly problem-
atic (e.g., if the patient suffers repeated injury from drop attacks, 
or is wheelchair-bound due to drop attack frequency). Re-evaluation 
with EEG and MRI is recommended before and after callosotomy 
to detect any changes resulting from the procedure (e.g., devel-
opment of focal seizures). Although VNS is less invasive than 
callosotomy, it still involves a surgical procedure and its use will 
therefore largely depend on patient/parent/caregiver choice. It can 
take time for the effects of VNS to become apparent, with further 
improvement over time. The decision as to when VNS should be 
used will depend on a variety of factors, including age, time since 
LGS diagnosis, and whether the patient has been experiencing 
troublesome or intolerable AEs with AED treatment. VNS can be 
used in conjunction with AED therapy following callosotomy.
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Patients with LGS That Has Evolved from Another 
Type of Epilepsy (e.g., West Syndrome)
Many patients will either have been treated with AED therapy 
to initially control seizures prior to LGS diagnosis, or will have 
developed LGS having progressed over time from another epilepsy 
syndrome, such as West syndrome. Most patients presenting with 
apparently generalized seizures will already be receiving VPA. 
If this is the case, then the treatment algorithm shown in Figure 1 
can be followed as for a de novo LGS patient (i.e., adding LTG 
as the first adjunctive therapy if VPA does not provide adequate 
seizure control, etc). If the patient is already being treated with 
another first-line AED (typically LEV), then VPA therapy should 
be initiated and the other therapy tapered off and discontinued. 
Thereafter, the treatment algorithm is the same as for a de novo 
LGS patient (Figure 1).
If the patient is being treated with more than one AED and nei-
ther is VPA, then VPA therapy should be initiated and one of the 
previous AEDs tapered off and discontinued. If seizure control 
is inadequate after introducing VPA and the second AED is not 
LTG, then LTG should be initiated and the other non-VPA AED 
tapered off and discontinued. Thereafter, the treatment algorithm 
is the same as for a de novo LGS patient (Figure 1).
Older Patients with established LGS
It is recommended that patients with established LGS should 
undergo review by a neurologist on at least an annual basis, com-
prising a thorough reassessment of their diagnosis (in terms of epi-
lepsy syndrome and etiology) and treatment plan. The diagnosis 
should be re-evaluated by repeating investigations conducted at 
initial diagnosis and/or conducting investigations that were previ-
ously not undertaken [EEG (including sleep-EEG, if possible), 
MRI, genetic testing], in order to confirm diagnosis and help eluci-
date etiology. Results of previous investigations should be reviewed 
alongside those of new investigations. Since the patient’s clinical 
and EEG features continue to evolve, a diagnosis other than LGS 
may become apparent and treatment should be adapted accord-
ingly. Clinicians should always be alert to the possibility that the 
diagnosis may change and be vigilant to the possibility of treatable 
etiologies. Clinicians should also be aware that the “classic” EEG 
features (SSW complexes) may evolve and/or disappear later in the 
disease course (16, 91). Loss of these features does not necessarily 
mean that the patient no longer has LGS, but this possibility must be 
considered alongside reassessment of other clinical/EEG features. 
Genetic counseling should be offered, if appropriate. EEG should 
be repeated whenever there are any concerns over diagnosis, signs 
of deterioration, or suspected NCSE.
Existing treatment should be re-evaluated in terms of its effec-
tiveness in controlling seizures, tolerability, impact on cognition/
behavior, and impact on QoL, and adjusted if necessary. Patient 
notes should be reviewed and discussed with the caring physician. 
Every attempt should be made to rationalize polytherapy: ideally 
try to use no more than two AEDs in combination, except when 
CLB or another benzodiazepine is used acutely for a crisis episode 
(e.g., cluster seizures, prolonged absences, NCSE). The patient/
parent/caregiver should be proactively asked about AEs and 
treatment adjusted accordingly. The patient’s cognitive ability and 
behavioral patterns should be reassessed regularly and treatment 
changed if it is suspected to be having a detrimental impact on 
the patient’s cognition/behavior. As for newly diagnosed patients, 
non-pharmacological treatment approaches should be consid-
ered alongside AED therapy when the patient’s treatment plan 
is reviewed. In adult patients, the withdrawal of treatment with 
a sodium channel blocker can be difficult, because generalized 
tonic–clonic seizures may appear. In such cases, slow tapering is 
recommended and the addition of CLB for a short period can be 
useful (92).
Management of NCSe
Up to three-quarters of patients with LGS experience episodes 
of NCSE (4). Its clinical presentation can vary from a mild 
confusional state to coma (93). However, presentation in this 
population may be quite subtle; by definition NCSE is a change 
in behavior and EEG from baseline (94). The diminished 
responsiveness may be insidious in its onset, and therefore may 
be missed. A high index of suspicion is therefore required on the 
part of the physician, particularly if a previous baseline EEG is 
not available for comparison (94). Patients with LGS should be 
regularly assessed for the development of possible NCSE, includ-
ing EEG, and, where possible, EEG results should be compared 
with a baseline recording (93). Expert advice may be required to 
confirm or refute a NCSE diagnosis.
Treatment for NCSE is less urgent than for convulsive status 
epilepticus12 and overtreatment should be avoided, since most 
patients do not require aggressive treatment. Patients should not 
be admitted to intensive care to induce an anesthetic treatment, 
since this could potentially be more harmful to the patient than 
the condition itself. NCSE should be treated with CLB and/
or steroids (expert opinion). High-dose intravenous VPA (to 
achieve a target plasma level of >100–130  μg/mL) can also be 
effective (95). The goal of treatment is to return the EEG to its 
pre-NCSE baseline pattern, and treatment should be optimized 
with ongoing review. Patients with NCSE should be referred for 
specialist advice and/or EEG monitoring (see text footnote 12).
Transition from Childhood to Adulthood
Transition from pediatric services into adult care is a difficult time 
for both patients and families, since educational provision ends and 
there are generally less resources available for adult than pediatric 
patients (3). Transition is particularly challenging for patients of 
intermediate age (16–17 years), since pediatric services are often 
reluctant to take on new patients of this age and keen to move 
existing patients to adult services (due to limited resources), while 
adult services will usually not take on patients aged <18  years. 
However, transition from pediatric to adult services also provides 
an important opportunity to carefully re-assess all aspects of 
patient care (3).
Etiology should be re-evaluated, using MRI and other inves-
tigations to exclude or detect specific etiologies that might affect 
treatment decisions; for example, tuberous sclerosis complex 
12 National Institute of Health and Care Excellence (NICE) Clinical 
guidel ine 137:  https ://www.nice.org.uk/guidance/cg137/resources/
epilepsies-diagnosis-and-management-35109515407813. 
FiGURe 2 | Schematic illustrating the increasing dispersion of care provision following transition from pediatric to adult services (3). Reproduced with permission 
from John Libbey Eurotext.
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(96, 97). In addition to reviewing previous EEG reports, a 
“baseline” EEG at the time of transition is recommended. AED 
treatment should be re-evaluated to determine whether it is 
the most appropriate for the patient at that time and the use 
of polytherapy should be rationalized and minimized wherever 
possible. Similarly, patients should be reassessed to determine 
whether non-pharmacological therapy should considered (or 
re-evaluated, if already used). The multidisciplinary needs of 
the patient and their family/carers should be reassessed, in 
terms of the requirement for social care support, psychiatric 
support, and the provision of community or residential care. 
An important aspect of transitioning from pediatric to adult 
services is that provision of care becomes increasingly dispersed 
(Figure 2) (3). Specialist “transition clinics” or “teenager clin-
ics” can help ease the transitional process (98, 99), and, for 
adolescent patients being treated with KD therapy, attendance 
at an adult epilepsy diet center can help ensure that an effective 
transition plan is in place (100). During the transition process, 
consideration should be given to the patient’s requirement for 
ongoing care by a physician with expertise in epilepsy (who 
may not necessarily be a neurologist). As previously stated, all 
patients should undergo at least annual review by a neurologist.
OTHeR CONSiDeRATiONS FOR LGS 
MANAGeMeNT
Lennox–Gastaut syndrome patients are impaired in their daily lives 
not only by a variety of seizure types that are often frequent and 
physically damaging (such as drop attacks), but also by a variety 
of serious comorbidities (3). Comorbidities that are particularly 
associated with LGS include cognitive and behavioral problems, 
physical disability, and sleep disturbances. Five years after LGS 
onset, 75–95% of patients have cognitive impairment (101, 102), 
and behavioral problems, such as hyperactivity, aggressiveness, 
and autistic traits, develop in approximately 50% (10). Mobility 
is often severely impacted by frequent seizures (particularly drop 
attacks), which are physically demanding and often result in 
injury (3). Patients often have to make use of protective equipment 
(such as a wheelchair, helmet, and/or faceguard) to minimize the 
physical effects of the seizures. Sometimes the use of protective 
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equipment (e.g., remaining in a wheelchair to protect against 
injury from drop attacks) can itself impact the mobility of patients, 
feeding into a vicious circle that limits their ability to be physically 
active. In addition, the early development of dysphagia is strongly 
associated with poor long-term seizure prognosis (103), and 
affects patients’ ability to eat and take medication.
Patients with LGS suffer sleep cycle disruption due to the 
occurrence of seizures at night. Sleep deprivation and/or disrup-
tion affect the neurophysiological and neurochemical mecha-
nisms important for the memory-learning process (104), and 
may also result in a wide range of behavioral, cognitive, and mood 
impairments, including hyperactivity, reduced school grades, and 
depression (105).
Careful management of comorbidities in LGS is a core aspect 
of care. Some AEDs may cause or exacerbate comorbidities 
(e.g., cognitive impairment, depression), and the choice of AED 
treatment must therefore take this possibility into consideration; 
for example, benzodiazepines used to treat sleep disorders may 
precipitate tonic seizures in LGS (106). Careful consideration must 
also be given to the potential for AED drug–drug  interactions 
with medications used for the treatment of comorbidities.
As a result of the substantial burden of seizures and 
 comorbidities, and the side effects of associated medications, the 
QoL of LGS patients is impaired on many levels (physical, mental, 
social) throughout their lives (3). The physical impact of LGS, and 
the preventative measures taken to minimize this impact, severely 
affect patients’ ability to participate in everyday activities, and school 
attendance is often disrupted. Cognitive and behavioral problems 
often require specific educational and care needs that will prevent 
mainstream school attendance (3). In addition, the aforementioned 
impact of nocturnal seizures on sleep can directly impair patients’ 
QoL (107). The effects of LGS on independence, ability to work, 
social participation, and personal relationships continue to severely 
impair patients’ QoL into adulthood (3). LGS also has a major 
impact on the QoL of parents/carers and families due to restriction 
of social life and relationship problems between partners and other 
family members; feelings of isolation, which can lead to depres-
sion; problems with childcare, which can further restrict social 
participation and opportunities for respite; physical exhaustion 
and/or disrupted sleep; anxiety about when seizures will occur, the 
future prospects of the individual with LGS, and the social stigma 
associated with the condition; as well as financial hardship resulting 
from forgoing career development in favor of caregiving (108).
Since LGS constitutes a major burden for patients and their 
caregivers/families, a multidisciplinary, individualized approach 
to care is required, which addresses each patient’s medical, edu-
cational, psychological, and social needs throughout the course of 
their life (109). The needs of the patient and their caregiver/family 
should ideally be re-evaluated annually, taking into account fac-
tors such as the patient’s physical health, their potential need for 
institutionalization (particularly in adulthood), and support for 
the caregiver/family.
AReAS FOR FUTURe ReSeARCH
At present, AEDs are anti-seizure medications and therefore 
treat the symptoms of epilepsy rather than its cause(s). Future 
research should focus on elucidating the natural history of LGS 
and whether appropriate treatment can have a beneficial impact 
on its disease course. This should not only include the effects of 
pharmacological treatment but also the role of surgical proce-
dures such as callosotomy. Early control of seizures in LGS has 
been suggested to be associated with improved neurocognitive 
outcomes (2), but the relevance of this in de novo LGS, as well as 
the impact of seizure suppression in older children and adults, is 
less certain, and is an area that warrants closer study. Although 
attention is currently given to the potential detrimental effects 
of AEDs on cognition, research is required to elucidate whether 
other non-AED treatments can protect against cognitive impair-
ment and/or improve cognition in LGS patients. In addition, 
research is needed to develop standardized tools for carers to 
routinely measure changes in patients’ cognitive performance and 
behavior over time. Elucidation as to whether there are specific 
genotypes or genetic mutations that determine a susceptibility 
to LGS is also needed, which could direct the development of 
diagnostic tools.
Given the problems associated with counting seizures in LGS 
(due to frequency of drop attacks, length of absence seizures, etc.), 
the predictive value of using alternative endpoints in clinical trials 
research should be assessed, such as the number of seizure-free 
days, rather than seizure frequency per  se. Characterization of 
factors that predict response to treatment in LGS patients would 
also be valuable in the research and clinical practice settings. 
Other potential areas of future research include the relevance of 
steroid therapy in LGS, and whether it can improve cognition 
[since there is some evidence of beneficial cognitive effects of 
steroid therapy for infantile spasms (110)], and the long-term 
effects of cannabidiol treatment in LGS, in terms of AEs and the 
potential development of tolerance.
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